Search

everythinglearnresearchcommunity

for

Search:↓

A 29-year-old woman is experiencing gradual hair thinning since age 15, suspects Androgenic Alopecia, and has tried 5% minoxidil with little success. She has purchased various hair loss treatments including minoxidil, dutasteride, finasteride, and spironolactone, but is cautious about starting them due to potential interactions with her ADHD medication.

A 15-year-old is concerned about hair loss, possibly at Norwood 2 or 3, and is using shampoos and conditioners recommended by a trichologist. Suggestions include considering topical minoxidil and consulting a doctor about topical anti-DHT treatments like finasteride or RU58841, but avoiding 5-alpha-reductase inhibitors at this age.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

A 104 year old man's impressive head of hair and speculations about how he has been able to maintain it; treatments such as minoxidil, finasteride, RU58841, dutasteride, 5-AR blockers, and other supplements are discussed.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

User asks if stacking Alfatradiol and Fluridil is effective for hair loss. Alfatradiol is a weaker, topical 5ar inhibitor, while Fluridil is an anti-androgen preventing DHT binding to hair follicles.

Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

Hair regrowth was achieved using minoxidil, nizoral, alfatrodial, and pyrilutamide after finasteride caused side effects. The user recommends this combination for those who can't tolerate 5AR inhibitors, stressing consistent use.

Minoxidil and Nizoral alone are unlikely to stop hair loss effectively, as they do not address the root cause, which is often DHT. Many users suggest incorporating a 5AR inhibitor like finasteride or dutasteride for better results, despite concerns about potential side effects.

DHT Itch and its link to balding, with various treatments such as finasteride being discussed. Members shared their experiences of scalp itch before and after taking 5AR inhibitors, and potential underlying causes such as seborrheic dermatitis were discussed.

A 17-year-old is looking for alternatives to finasteride for DHT control to preserve hair, considering ketoconazole shampoo for its potential to inhibit 5AR and also thinking about using caffeine-containing shampoos like alpecin or watermans.

User experienced hair regrowth after eliminating scalp itch with RU58841. Others discussed itch and hair loss connection, and effectiveness of combining RU58841 with 5AR inhibitors.

A user shared their frustration about their cousin's refusal to take their advice on using finasteride for aggressive hair loss, despite the cousin's desperation and current use of minoxidil and consideration of PRP injections. The user, who has done extensive research, suggested the cousin needs a 5ar inhibitor, but the cousin dismisses the advice because the user isn't a doctor.

The user has been using oral finasteride and minoxidil for 1.5 years with some crown improvement but still experiences thin hair and a receding hairline. They are considering switching to dutasteride for potentially better results, while others suggest adding topical minoxidil back into the routine.

The conversation discusses a user's two-month hair regrowth progress using Minoxidil and a 0.5mm dermaroller. Some suggest adding a 5-alpha-reductase inhibitor like finasteride or dutasteride to maintain the results.

The user has been using finasteride and minoxidil for 8-9 months without significant improvement in hair loss and is considering switching to dutasteride and topical minoxidil. Another user suggests that dutasteride might be more effective due to its potency and advises patience as hair regrowth can take up to a year.

CBD may increase hair counts slightly, but results are minimal without additional treatments like minoxidil or finasteride. Some users suggest combining CBD with other methods for better results.

An 18-year-old began using Finasteride and Topical Minoxidil for hair loss, later switching to Oral Minoxidil and Dutasteride by age 25. The conversation emphasizes early treatment, potential side effects, and differing opinions on medication effectiveness.

Ketoconazole shampoo is primarily for scalp health and reducing inflammation, not hair regrowth. Combining ketoconazole with finasteride can yield similar results to using minoxidil and finasteride together.

A 21-year-old male has been experiencing persistent hair loss despite using treatments like dutasteride, finasteride, RU58841, minoxidil, and ketoconazole. Suggestions include checking for hormonal issues, nutritional deficiencies, or allergies, and consulting a doctor for professional advice.

A user's 23 year experience with Finasteride/Dutasteride and their current consideration of adding Minoxidil to their treatments for hair loss.

The user used Minoxidil 5% for 18 months, seeing improved hair density but no change in the crown area. They are cautious about using Finasteride again due to past gynecomastia.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The user has been using minoxidil twice daily for 2.5 months to treat hair loss and has seen great results, despite only microneedling once at the start. They occasionally forget a dose but it hasn't affected their positive outcome.

A 21-year-old is using oral minoxidil, rosemary oil, saw palmetto, and pumpkin seed oil for hair regrowth but is advised to use finasteride or dutasteride for better results. The user is hesitant to use DHT blockers due to cost and is seeking advice on whether their current regimen is effective.

The user is disappointed with their hair loss treatment results using Minoxidil, dermastamping, and ketoconazole shampoo. They are advised to add Finasteride or Dutasteride to block DHT for better results.

HMI-115 shows promising hair growth and thickening in just 2 months. Results are positive but need more time for confirmation.

A user shared their positive experience with a hair transplant of 3500 grafts, showing significant improvement in appearance after 5 months. They underwent the procedure at Heva Clinic in Istanbul for $2,300 USD, which included aftercare, and attributed their hair loss to both genetics and traction alopecia from tight hairstyles.

The conversation discusses the effectiveness and side effects of taking 1.25mg oral minoxidil for hair loss, with some users suggesting starting at a lower dose to minimize side effects before potentially increasing to 2.5mg. Concerns about cardiovascular side effects and the importance of individual responses to dosage are highlighted.